Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/31709
Title: Comparison of clinical outcomes of different erythropoietin usage strategies
Authors: Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.
0000-0003-2501-3097
Arslan, Murat
Evrensel, Türkkan
Kurt, Ender
Demiray, Mutlu
Gönüllü, Güzin
Kanat, Ozkan
Manavoğlu, Osman
M-8060-2019
57197925370
6603942124
7006207332
6603631569
6506410014
55881548500
6602587152
Keywords: Oncology
Anemia
Cancer
Erythropoietin
Platinum
Recombinant-human-erythropoietin
Chemotherapy-induced anemia
Quality-of-life
Cisplatin-associated anemia
Epoetin-alpha
Transfusion requirements
Trial
Prevention
Issue Date: 2004
Publisher: Sage Publications
Citation: Arslan, M. vd. (2004). “Comparison of clinical outcomes of different erythropoietin usage strategies”. Tumori Journal, 90(4), 394-398.
Abstract: Aim: There is no comprehensive study that compares the different usage strategies of recombinant human erythropoietin (rHuEPO) in platinum-induced anemia. In order to clarify this issue, we conducted a prospective clinical study. Material and methods: Seventy-seven patients were studied in three main groups. Group 1 (n = 17) consisted of cancer patients without anemia. These patients received rHuEPO starting from the first chemotherapy cycle. Group 2 (n = 26) consisted of patients whose hemoglobin (Hb) values decreased by at least 1 g/dL after the first cycle of chemotherapy. Group 3 (n = 34) consisted of patients whose Hb values dropped below 10.5 g/dL after the second chemotherapy cycle. Groups 2 and 3 were each divided into two subgroups. In groups 1, 2A and 3A rHuEPO (5000 U/day subcutaneously three times a week) treatment was continued until three weeks after the completion of chemotherapy. In groups 2B and 3B, rHuEPO was given for 12 weeks only. Results: There were no prominent differences between the Hb values of these groups throughout the chemotherapy cycles. Transfusion rates and the number of patients who became anemic were also not different between groups. Conclusion: No rHuEPO usage strategies are superior to others in terms of Hb levels and transfusion requirements. The decision as to when rHuEPO is to be added to platinum-containing therapy should be tailored to the health conditions of individual patients.
URI: https://doi.org/10.1177/030089160409000406
https://journals.sagepub.com/doi/10.1177/030089160409000406
http://hdl.handle.net/11452/31709
ISSN: 0300-8916
Appears in Collections:Scopus
Web of Science

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.